Scientists recreate blood-brain barrier on a chipScientists in Israel and the US have duplicated the blood-brain barrier in a chip using human stem cells, Share XScientists recreate blood-brain barrier on a chiphttps://pharmaphorum.com/news/scientists-recreate-blood-brain-barrier-on-a-chip/
Roche’s Gazyva shows promise in Lupus nephritis trialRoche’s Gazyva is already approved in leukaemia and lymphoma – but could it work in the autoimmune kidney Share XRoche’s Gazyva shows promise in Lupus nephritis trialhttps://pharmaphorum.com/news/roches-gazyva-shows-promise-in-lupus-nephritis-trial/
Exscientia begins China AI drug discovery tie-up with GT ApeironUK Artificial Intelligence (AI) drug discovery firm Exscientia has begun a collaboration with China’s GT Apeiron Therapeutics, focusing Share XExscientia begins China AI drug discovery tie-up with GT Apeironhttps://pharmaphorum.com/news/exscientia-begins-china-ai-drug-discovery-tie-up-with-gt-apeiron/
Digital tool aims to cut costs and risks of underperforming trialsArcheMedx, which provides tech solutions for life sciences and healthcare, has launched a new digital service that aims Share XDigital tool aims to cut costs and risks of underperforming trialshttps://pharmaphorum.com/news/digital-tool-aims-to-cut-costs-and-risks-of-underperforming-trials/
Relax criteria to increase sign-ups to cancer trials, says ASCOOnly 3% of patients with cancer in the US enrol on a clinical trial – and the American Share XRelax criteria to increase sign-ups to cancer trials, says ASCOhttps://pharmaphorum.com/news/relax-criteria-to-increase-sign-ups-to-cancer-trials-says-asco/
MacroGenics looks to future with breast cancer drug margetuximabA small biotech, MacroGenics, took the market by surprise earlier this year with some surprising data from its Share XMacroGenics looks to future with breast cancer drug margetuximabhttps://pharmaphorum.com/news/macrogenics-looks-to-future-with-breast-cancer-drug-margetuximab/
The future of R&D innovationAlexander Gray and Mike Rea from IDEA Pharma explain why the current pharma R&D model is broken, and Share XThe future of R&D innovationhttps://deep-dive.pharmaphorum.com/magazine/access-and-commercialisation/idea-pharma-future-research-innovation/
Dynavax cuts staff and cancer R&D, focuses on vaccineUS biotech Dynavax has announced staff cutbacks after deciding to focus on its vaccine business, while winding down Share XDynavax cuts staff and cancer R&D, focuses on vaccinehttps://pharmaphorum.com/news/dynavax-cuts-staff-and-cancer-rd-focuses-on-vaccine/
Daiichi Sankyo in talks over OTC unit sale – reportsDaiichi Sankyo is in talks with several companies over a sale of its over-the-counter (OTC) business, according to Share XDaiichi Sankyo in talks over OTC unit sale – reportshttps://pharmaphorum.com/news/daiichi-sankyo-in-talks-over-otc-unit-sale-reports/
